Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Liabilities and Shareholders Equity (2021 - 2025)

Historic Liabilities and Shareholders Equity for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $1.2 billion.

  • Krystal Biotech's Liabilities and Shareholders Equity rose 2624.16% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 billion, marking a year-over-year increase of 2623.78%. This contributed to the annual value of $1.1 billion for FY2024, which is 2901.96% up from last year.
  • Latest data reveals that Krystal Biotech reported Liabilities and Shareholders Equity of $1.2 billion as of Q3 2025, which was up 2624.16% from $1.1 billion recorded in Q2 2025.
  • Krystal Biotech's Liabilities and Shareholders Equity's 5-year high stood at $1.2 billion during Q3 2025, with a 5-year trough of $443.0 million in Q1 2021.
  • In the last 5 years, Krystal Biotech's Liabilities and Shareholders Equity had a median value of $684.0 million in 2023 and averaged $758.1 million.
  • In the last 5 years, Krystal Biotech's Liabilities and Shareholders Equity plummeted by 1378.35% in 2023 and then soared by 6044.01% in 2024.
  • Krystal Biotech's Liabilities and Shareholders Equity (Quarter) stood at $626.3 million in 2021, then fell by 10.83% to $558.4 million in 2022, then skyrocketed by 46.54% to $818.4 million in 2023, then grew by 29.02% to $1.1 billion in 2024, then grew by 17.45% to $1.2 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.2 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $1.1 billion for Q1 2025.